-
公开(公告)号：US20190388471A1
公开(公告)日：2019-12-26
申请号：US16435257
申请日：2019-06-07
发明人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph A. Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Jonathan Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
IPC分类号： A61K35/17 , A61K39/395 , A61K31/519 , A61K45/06 , C07K14/725 , A61K31/436 , A61K31/53 , C12N5/0783 , C07K16/28
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
公开(公告)号：US20190384604A1
公开(公告)日：2019-12-19
申请号：US16062796
申请日：2016-12-12
发明人： André Dehon , Catalin Hritcu , Udit Dhawan
摘要： Techniques are described for metadata processing that can be used to encode an arbitrary number of security policies for code running on a processor. Metadata may be added to every word in the system and a metadata processing unit may be used that works in parallel with data flow to enforce an arbitrary set of policies. In one aspect, the metadata may be characterized as unbounded and software programmable to be applicable to a wide range of metadata processing policies. Techniques and policies have a wide range of uses including, for example, safety, security, and synchronization. Additionally, described are aspects and techniques in connection with metadata processing in an embodiment based on the RISC-V architecture.
-
公开(公告)号：US20190151365A1
公开(公告)日：2019-05-23
申请号：US16321322
申请日：2017-07-28
发明人： Oezlem Anak , Sanela Bilic , Jennifer Brogdon , John Scott Cameron , William Chou , Stephan Grupp , Danny Roland Howard, Jr. , Randi Isaacs , Carl H. June , Simon Lacey , Shannon Maude , Jan J. Melenhorst , Stephen Shuster , Alfonso Quintas-Cardama
IPC分类号： A61K35/17 , C07K14/725 , C07K16/28 , A61P35/00 , G01N33/574
摘要： Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD-1 inhibitor.
-
公开(公告)号：US20240353364A1
公开(公告)日：2024-10-24
申请号：US18640633
申请日：2024-04-19
发明人： Kevin T. Turner , Gokulanand Meenakshisundaram Iyer , Gnana Saurya Vankayalapati , Michael Machold
CPC分类号： G01N27/223 , G01N33/246
摘要： A composite, comprising: a first surface, a second surface, and a thickness between the first surface and the second surface, a porous scaffold having a plurality of pores extending from the first surface into the thickness, at least some of the plurality of pores being at least partially filled with cellulose nanofibrils, and the first surface of the composite having a root mean square (RMS) roughness of from about 0.01 to about 0.1 μm.
-
公开(公告)号：US20240342280A1
公开(公告)日：2024-10-17
申请号：US18293729
申请日：2022-08-09
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N15/113
CPC分类号： A61K39/4611 , A61K39/4631 , A61K39/464412 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2803 , C12N5/0636 , C12N15/113 , A61K2239/22 , C07K2317/53 , C07K2319/02 , C07K2319/03 , C12N2310/141 , C12N2510/00
摘要： The current invention includes compositions and methods comprising immune effector cells modified to express miR-29a for the purpose of resisting immune exhaustion. In various embodiments the transmembrane domain comprises a transmembrane region of a protein selected from the group consisting of a type I transmembrane protein, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, a zeta chain of a T cell receptor, CD28, CD2, CD3 epsilon, CD45, CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134 (OX-40), CD137 (4-1BB), CD154 (CD40L), CD278 (ICOS), CD357 (GITR), Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9.
-
6.发明公开公开(公告)号：US20240342213A1
公开(公告)日：2024-10-17
申请号：US18416459
申请日：2024-01-18
发明人： Carl H. June , Michael Milone , Yangbing Zhao , Lawrence G. Lum , Archana Thakur
IPC分类号： A61K35/17 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/32 , C12N5/0783 , A61K35/00 , A61K39/00
CPC分类号： A61K35/17 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C12N5/0636 , A61K35/00 , A61K39/0011 , A61K2039/5156 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C07K2319/43 , C07K2319/50
摘要： The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.
-
公开(公告)号：US12116418B2
公开(公告)日：2024-10-15
申请号：US17029702
申请日：2020-09-23
发明人： Steven A. Albelda , Ellen Puré , Leslie Todd
IPC分类号： C12N15/13 , A61K35/17 , A61K45/06 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/40 , C12N5/0783
CPC分类号： C07K16/40 , A61K35/17 , A61K45/06 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C12N5/0638 , C07K2317/33 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2319/03
摘要： The present invention relates to compositions and methods comprising a chimeric antigen receptor (CAR) capable of binding fibroblast activation protein (FAP) for use in treating diseases, disorders or conditions associated with the expression of FAP on canine, mouse, or human tumor-associated cells.
-
公开(公告)号：US20240339206A1
公开(公告)日：2024-10-10
申请号：US18542492
申请日：2023-12-15
发明人： Insup Lee , Hyonyoung Choi , Amanda Lor , Michael Megonegal , Xiayan Ji , Amanda Watson , Jean Park , Oleg Sokolsky
摘要： A system for managing a plurality of medical devices includes a stream processor for receiving medical data from a plurality of medical devices and for generating metadata and storing the medical data and the metadata for each of the devices. The system further includes data storage for storing the medical data and the metadata. The system further includes a communications interface for implementing at least one communications protocol for providing access to the medical data and the metadata. The system further includes an application for accessing the medical data and the metadata via the communications interface and generating, based on the medical data and the metadata, output indicative of operating status of the medical devices.
-
公开(公告)号：US20240328997A1
公开(公告)日：2024-10-03
申请号：US18587324
申请日：2024-02-26
发明人： Aaron Timperman
IPC分类号： G01N27/447 , B01L3/00
CPC分类号： G01N27/44791 , B01L3/502761 , B01L2300/0645
摘要： A method, comprising: determining electrophoretic mobility associated with a particle in a transverse alternating force microfluidic channel; determining a size of the particle based at least in part on one of Brownian motion of a particle or one or more images of the particle. A system comprising: a microfluidic channel; a plurality of electrodes oriented transverse to the microfluidic channel, the plurality of electrodes comprising an alternating electric field; and a classification system configured to: determine one or more of the following: an electrophoretic mobility associated with a particle in the transverse AC microfluidic channel and/or determine, based at least in part on the electrophoretic motion, and size from image analysis or Brownian motion of a particle or one or more images of the particle, particle shape, particle deformability, for recognition of surface characteristics, such as assaying for receptors and ligands, and to perform electroporation.
-
公开(公告)号：US12104152B2
公开(公告)日：2024-10-01
申请号：US16982467
申请日：2019-03-18
IPC分类号： C07H21/04 , A61P21/00 , C12N15/113
CPC分类号： C12N15/113 , A61P21/00
摘要： The invention relates to compositions and methods for enhancing or upregulating utrophin protein production and methods for treating myopathies, such as Duchenne Muscular Dystrophy (DMD). Specifically, the invention relates to compositions, such as oligonucleotides, and methods for enhancing or upregulating utrophin in a subject by blocking binding of let-7c miRNA to the utrophin mRNA 3 untranslated region (UTR).
-
-
-
-
-
-
-
-
-
搜索结果
3574 条记录 (耗时 0.062 秒)
